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ABSTRACT 
The aim of this study was to assess the relationship between pre-prostatectomy urinary Engrailed-2 (EN2), a transcrip-
tion factor secreted by prostate cancer cells, with tumour volume and pathological characteristics in resected prostate 
specimens. First pass urine samples (10 ml) without prior prostatic massage were collected and stored at –80˚C. EN2 
levels were measured using an enzyme-linked immunoabsorbent assay. Tumour volume in the prostatectomy specimens 
was determined histologically. 57 men undergoing RP in one urological cancer network were evaluated. EN2 was de-
tected in 85% of RP patients. EN2 correlated with tumour volume (but not total prostatic volume) in a linear regression 
analysis, with increasing pathological T stage and margin positivity. Using three “cutoff levels” of tumour volume (0.5 
ml, 1.3 ml and 2.5 ml) to define “significant disease”, men with “significant disease” had markedly higher levels of uri-
nary EN2 (p < 0.001 for each cut off level). Levels of urinary EN2 may be useful in predicting tumour volume in men 
with prostate cancer by potentially identifying men with small volume “insignificant” disease. This study justifies a 
larger multicentre evaluation of urinary EN2 levels as a biomarker of PC significance using cancer volume, pathological 
and PSA criteria. 
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1. Introduction 
For over 20 years, prostate specific antigen (PSA) testing 
has provided the opportunity for the detection of prostate 
cancer (PC) at an earlier and, therefore, more likely cura-
tive stage of the disease. Although PSA has been (and 
remains) a valuable cancer biomarker, the limited sensi-
tivity and specificity of PSA for cancer at the age-spe- 
cific cut-offs [1,2] and its elevation in benign prostate 
disorders continues to limit its utility. In addition, there is 
no consistent correlation between PSA and the grade, 
stage or volume of disease [3]. Attempts to increase the 
predictive value of PSA using PSA density and velocity, 
the ratio of free to total PSA and different PSA isoforms 
have made little impact clinically [4]. There is an urgent 
need for novel biomarkers which aid clinical decision 
making with respect to biopsy and primary therapy [5]. 
We reported the potential diagnostic utility of En-
grailed-2 (EN2), a transcription factor involved in em-
bryonic brain development that is re-expressed in PC [6]. 
The presence of EN2 in urine was predictive of PC, with 
a sensitivity of 66% and a specificity of 88.2% (AUC of 
0.81).  We further demonstrated a strong positive corre-
lation between pre-surgical levels of urinary EN2 and 
tumour volume in RP specimens in a retrospective series, 
as well as a correlation between EN2 levels and tumour 
stage (T2 vs. T3) [7].  
The objective of the current study was to prospectively 
examine the relationship of pre-surgical urinary EN2 
levels with tumour stage and tumour volume in RP spe-
cimens and thereby to provide an indication whether 
EN2 could potentially be used, in conjunction with other 
criteria, to designate patients as suitable for immediate 
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active treatment versus active surveillance. 
2. Materials and Methods 
2.1. Patients 
The patients were recruited to the study between De-
cember 2010 and February 2012. Patients were identified 
in multidisciplinary uro-oncology clinics from the Surrey, 
West Sussex and Hampshire Cancer Network, UK. All 
patients gave written informed consent and the study 
received approval by the local ethics committee (REF: 
09/H1109/98). Patients were recruited prospectively and 
consecutively and not selected in any way apart form the 
following criteria. The main criterion for inclusion was 
planned RP (laparoscopic or robotic) for clinically local-
ised PC. The diagnosis of PC was established based on 8 - 
12 core (transrectal sextant and/or template biopsies).  
Patients with a urinary tract infection, on any therapy for 
PC or on finasteride, with non-organ confined disease 
and any histologically confirmed second malignancies 
were excluded.  
Serum PSA was measured 1 - 2 weeks prior to urine 
procurement. First pass urine samples (10 ml), without 
prostatic massage, were collected a minimum of 4 weeks 
after any biopsy procedure (sextant or template) and, in 
general, were between 1 day and 2 weeks before RP. We 
previously reported that EN2 protein is stable in urine at 
room temperature for at least 4 days [6], and all urine 
samples were received for processing within 30 hours 
post donation. Upon receipt in the laboratory, samples 
were divided into 1.5ml aliquots, centrifuged 10,000 g 
for 5 minutes and the supernatant removed and stored at 
–80˚C.  
All RP specimens and biopsies were evaluated by a 
specialist uro-pathologist. Tissue samples were fixed in 
10% formalin, paraffin embedded, and sectioned at 5- 
mm intervals before mounting of whole sections on 
slides. In conducting a complete sampling procedure, the 
apical portion, the base, and the neck of the prostate were 
separated and sampled using a cone technique. The 
Gleason grading system (International Society of Uro-
logical Pathology revised version) was applied and the 
TNM classification for staging was used. Each focus of 
PC was outlined on the histology sections and tumour 
volume calculated by multiplying the area by the section 
thickness. The individual volumes of mutifocal tumours 
were calculated and combined as the total tumour vol-
ume. 
2.2. Enzyme-Linked Immunosorbent Assay 
A modified version of the previously published ELISA 
method [6] was used for this study. EN2 was bound di-
rectly to the surface of a plastic assay plate (Nunc Max-
isorb) by incubating urine in each well for 2 hours. The 
wells were subsequently washed with PBS with 0.1% 
Tween 20, and the EN2 protein bound to the plastic sur-
face was detected using a mouse anit-EN2 monoclonal 
antibody linked to alkaline phosphatase. Samples were 
tested anonymously to eliminate patient identification. 
100 µl of the urine supernatant samples or a dilution of 
the EN2 fragment in buffer was tested in duplicate. A 
standard curve was generated from dilution series to al-
low the concentration of EN2 in each sample to be 
measured. 
2.3. Statistical Analysis 
The GraphPad Prism (GraphPad Software Inc, USA) 
package was used in statistical calculations. To test the 
significance of differences between mean EN2 concen-
trations in different patient groups (defined by T-stage or 
Gleason grade) an unpaired t-test with Welch’s correc-
tion was used as the EN2 values were not normally dis-
tributed. Correlations between PSA and tumour volume/ 
prostate volume, and EN2 and tumour volume/prostate 
volume were calculated by linear regression. Receiver 
operator characteristics (ROC) curves were generated for 
the EN2 and PSA values. The area under the curve was 
tested for significance using an unpaired t-test against the 
hypothesis that the real area under the curve was 0.5 (i.e. 
no diagnostic value). The threshold value for significance 
of EN2 level in urine was set at 42.5 ng/ml based on the 
original study [6]. 
3. Results 
3.1. Patient Characteristics 
The patient characteristics of the 57 men in the study are 
shown in Table 1. Clinical stages T1c, T2a, T2b and T3a 
were reported in 36, 8, 8, 4 and 1 man, respectively. The 
mean number of positive cores was five (median 5, in-
terquartile range (IQR) 3-7). The median combined 
Gleason score in biopsies and RP specimens was 7, IQR 
6-7). Seventeen patients had their Gleason score up-
graded after RP; two patients were downgraded. The RP 
Gleason scores were as follows: 3 + 3 (n = 15); 3 + 4 (n 
= 33); 4 + 3 (n = 5); 4 + 4 (n = 0); 3 + 5 (n = 3); and 4 + 
5 (n = 1). The pathological grades in the RP specimens 
were: Gleason 6 (26.3%); 7 (66.6%), 8 (5.2%) and 9 
(1.7%).  
The mean tumour volume in the RP specimen was 
4.92 ml (median 4.35 ml, IQR 1.81-6.7ml). EN2 levels 
across the cohort were not normally distributed. Of the 
total of 57 patients in the cohort, 85% were positive for 
EN2 in their urine having levels above 42.5 ng/ml de-
scribed previously) [6]. In these men, the mean EN2 level 
in urine was 347.73 ng/ml (median 265, IQR 184-524). 
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The demographic and pathological features of patients 
who were positive or negative for EN2 secretion are 
shown in Table 2. The groups differed only on the basis 
of tumour volume, where EN2 secretion was associated 
with larger tumour volume at prostatectomy. The differ-
ence between the mean EN2 levels between the two 
groups was statistically significant (p ≤ 0.0001). The 
difference between the mean tumour volume between the 
two groups was also statistically significant (p ≤ 0.0001).  
In eight of the nine men who were not secreting EN2, 
one or more of their original diagnostic prostatic biopsies 
were positive for EN2 staining (data not shown). 
3.2. Correlation between Serum PSA, Urinary 
EN2 and Pathological Findings 
No correlation was found between serum PSA level and 
levels of urinary EN2 in pre-RP samples (p = 0.075; 
Figure 1). Higher levels of EN2 were detected in more 
advanced clinical T stage but this did not reach signifi-
cance (p = 0.1936). However, digital rectal examination 
prediction is notoriously variable between individuals 
and is of limited value in staging. Regarding pathological 
stage, significant differences were noted in the median 
levels of EN2 in pT2 (n = 39) and pT3a (n = 19), which 
were 210 ng/ml (IQR 52 ng/ml - 347 ng/ml) and 420 
ng/ml (IQR 282 ng/ml - 662 ng/ml) respectively (p = 
0.0063) (Figure 2). Men with positive margin(s) had 
significantly higher median levels of EN2 in margin pos-
itive patients (n = 14) of 554.5 ng/ml (IQR 354.2 ng/ml - 
733.7 ng/ml) versus 227 ng/ml (IQR 90.25 ng/ml - 375 
ng/ml) in margin negative patients (n = 43) (p = 0.0078) 
(Figure 3). Although men with perineural invasion 
showed the same trend, this did not achieve statistical 
significance (data not shown). 
The relationship between urinary EN2 and serum PSA 
and Gleason grading of biopsies and RP specimens was 
examined. In the biopsies, higher levels of EN2 were 
associated with Gleason 7 disease compared with Glea-
son 8, although there were far fewer cases of Gleason 8. 
In the RP specimens, there were equally high levels in 
Gleason 6 and 7 and again lower levels in Gleason 8.  
 
Table 1. Patient characteristics of 57 men included in 
Radical Prostatectomy group. 
 Mean Median Range 
Age(years) 64.8 66 48 - 77 
PSA (mg/L) 9.1 8 2.4 - 27 
EN2 (ng/ml) 347.73 265 0 - 1129 
Tumour volume (ml) 4.92 4.35 0.15 - 14.8 
Total prostatic volume (ml) 46.2 40 13.7 - 160 
Table 2. Demographic and pathological features of patients who 
were positive or negative for EN2 secretion. The difference between 
the mean EN2 levels between the two groups was statistically sig-
nificant (p ≤ 0.0001). The difference between the mean tumour 
volume between the two groups was also statistically significant (p 
≤ 0.0001). 
 
Non EN2 Producer 
i.e. < 42.5 ng/ml n = 9  
(16%) 
EN2 Producers 
i.e. > 42.5 ng/ml n = 48 
(84%) 
Age (years) 
Mean 64.3 64.9 
Median 67 66 
Range Min. 49 48 
Max. 73 77 
PSA ng/ml 
Mean 8.08 9.81 
Median 6.4 9.1 
Min. 4.47 2.4 
Max. 23 29 
EN2 ng/ml 
Mean 7.5 411.52 
Median 0 331.5 
Min. 0 68 
Max. 36 1129 
Tumour Volume on RP cc 
Mean 1.06 5.65 
Median 0.82 5.2 
Min. 0.15 0.3 
Max. 2.75 14.8 
Prostate Volume cc 
Mean 47 46 
Median 49 40 
Min. 21 13.7 
Max. 90 160 
Sum Gleason on Biopsy 
Mean 6 7 
Median 6 7 
Min. 6 6 
Max. 7 7 
Sum Gleason on RP 
Mean 7 7 
Median 7 7 
Min. 6 6 
Max. 7 9 
 
Differences did not reach statistical significance in either 
the biopsy or RP sampling group. PSA levels varied to a 
lesser extent than EN2 levels in relation to Gleason lesser 
extent than EN2 levels in relation to Gleason grading in 
biopsy and RP specimens; in both cases this did not 
reach statistical significance. 
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Figure 1. Correlation between levels of serum prostate- 
specific antigen (PSA) and pre-prostatectomy urinary En-
grailed-2 (EN2) levels. 
 
p = 0.0063**            
 
Figure 2. Comparison of pre-prostatectomy urinary En-
grailed-2 (EN2) levels in PT2 versus pT3 prostate cancers. 
 
p = 0.0078**            
 
Figure 3. Comparison of pre-prostatectomy urinary En-
grailed-2 (EN2) levels in patients with positive and negative 
resection margins in the RP specimen. 
3.3. Correlation of Pre-Prostatectomy Urinary 
EN2 Levels and Serum PSA with Total 
Prostate and PC Volume 
There was no significant correlation between PSA level 
and total prostate gland volume (p = 0.2846; Figure 4(a)) 
or PC volume (p = 0.0909; Figure 4(b)). Similarly no 
correlation was found between EN2 levels and prostate 
gland volume (p = 0.2846; Figure 5(a)). In contrast, a 
very strong correlation was identified between tumour 
volume and EN2 levels (p = 0.0001; Figure 5(b)). 
Several studies have shown small prostate cancers are 
unlikely to progress locally and and/or metastasise, and 
therefore may represent “insignificant” disease not re-
quiring immediate treatment [8,9]. Based on these previ-
ous studies, 3 volume cut offs of 0.5 ml, 1.3 ml and 2.5 
ml were selected and the potential of PSA and EN2 lev-
els to indicate significant disease was tested. PSA was 
unable to distinguish between significant and insignifi-
cant disease using cut offs of 0.5 ml and 1.3 ml (Figures 
6 (a) and (b)). In contrast, a highly significant difference 
between cancers using all three cutoff levels was ob-






Figure 4. Relationship between pre-prostatectomy prostate- 
specific antigen (PSA) levels and (a) prostate volume and (b) 
total tumour volume. 
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Figure. 5. Relationship between pre-prostatectomy urinary 
Engrailed-2 (EN2) levels and (a) prostate volume and (b) 
tumour volume. 
 
p = 0.8668 
 
(a) 
p = 0.5555 
 
(b) 
p = 0.0513 
 
(c) 
Figure 6. Relationship between prostate-specific antigen 
(PSA) level and prostate tumour volume (TV) using cutoff 
points of (a) ≤ 0.5 ml and > 0.5 ml; (b) ≤ 1.3 ml and > 1.3 ml; 
and (c) ≤ 2.5 ml and > 2.5 ml. 
4. Discussion 
The unmet need for biomarkers for prostate cancer now 
includes not only improved diagnostic sensitivity and 
specificity, but also whether any tumour detected re-
quires immediate treatment or can be safely monitored. 
Small prostate cancers have a low propensity to progress 
locally and metastasize [10,11]. Non-invasive methods of 
reliably identifying these small cancers would have high 
clinical utility. Our retrospective study showed a signifi-
cant correlation between pre-surgical urinary EN2 and 
tumour volume, but included what would currently be 
regarded as a high-risk population and evaluated samples 
from a biobank collected during non-contemporary clinical 
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p < 0.0001*** 
 
(a) 
p < 0.0001*** 
 
(b) 
p < 0.0001*** 
 
Figure 7. Relationship between pre-prostatectomy urinary 
Engrailed-2 (EN2) levels and prostate tumour volume (TV) 
using cutoff points of (a) ≤ 0.5 ml and > 0.5 ml; (b) ≤ 1.3 ml 
and > 1.3 ml; and (c) ≤ 2.5 ml and > 2.5 ml. 
practice in terms of patient imaging, biopsy techniques 
and surgical prostatectomy techniques [7]. It was thus felt 
important to evaluate EN2 in a prospective study reflect-
ing current practice, diagnostic and surgical techniques. 
Compared to the previous retrospective study, we evalu-
ated the relationship between pre-surgical levels of EN2 
in urine and pathological features in a lower risk RP 
group. 
The relationship between PSA and tumour volume has 
been extensively investigated as both PSA and tumour 
volume are independent predictors of outcome [12]. In 
this study, the RP population was representative of con-
temporary practice with 63% of men presenting with T1c 
disease. Most men (85%) in this study had significant 
levels of EN2 in their urine. There was a strong correla-
tion between EN2 and tumour volume (p < 0.001) and 
pathological T stage (pT2 versus pT3a p < 0.0063). 
There was no correlation between PSA levels with either 
tumour volume or total prostatic volume. There was also 
a significant correlation with margin positivity. No statis-
tical differences in EN2 and PSA levels and Gleason 
grade were evident: this is understandable in terms of 
patient selection for RP in this study, and will be evalu-
ated again in an ongoing prospective study involving a 
number of PC diagnostic biomarkers in addition to EN2. 
Low volume PC (< 0.5ml) is considered to have a low 
potential to metastasize and this cutoff has been used to 
designate cancers as being insignificant [9]. A recent 
analysis of prostatectomy patients within the ESPRC 
(The European Randomized study of Screening for Pros-
tate Cancer) study proposed that the threshold volume for 
significance may be higher: 1.3 ml and 2.5 ml for index 
lesion and total volume respectively [9]. There may be 
considerable clinical value in a pre-treatment tumour 
marker that provides an accurate assessment of cancer 
volume in terms of assessing PC progression risk i.e. to 
identify patients suitable for active surveillance (AS). We 
found that when using any of the three tumour volumes 
cited above, there was a highly significant difference in 
EN2 levels above and below these cut offs.  
Patients on AS, by definition, should have small vol-
ume and low risk disease. One of the key objectives of 
the AS concept is that after identifying suitable patients 
there is continual evaluation during follow up to see if 
they should remain in AS or be treated. There are cur-
rently no good markers of progression in these patients, 
including PSA, necessitating repeated biopsy. There are 
indications that Gleason 7 disease may be significant 
whereas Gleason 6 may not. In our study we did not de-
tect a difference in EN2 levels between Gleason 6 and 7 
patients, although such a correlation may be better ex-
plored with a larger cohort. Our results to date and the 
simplicity and low cost of EN2 testing justifies a pro-
Copyright © 2013 SciRes.                                                                                  JCT 
Correlation of Urinary Engrailed-2 Levels to Tumour Volume and Pathological Stage  
in Men Undergoing Radical Prostatectomy 
732 
spective study of 6 monthly urinary EN2 testing in con-
junction with other AS criteria, and this study is currently 
being designed.  
There are currently large numbers of potential PC 
biomarkers in blood, urine and tissue under evaluation 
(reviewed in [13]). A significant association between low 
PCA3 scores and low tumour stage and grade has been 
reported [14,15]. In contrast, other studies have identified 
a correlation between high PCA3 scores and extra cap-
sular extension [16], or have indicated no correlation 
with tumour volume or tumour grade [17,18]. Low levels 
of PCA3 were shown to correlate with low volume pros-
tate cancer but not with higher volume and stage disease 
in the largest prospective study to date [19]. A logical 
future study would be to evaluate potential synergy of 
EN2 (predicting cancer volume) and PCA3 (predicting 
extracapsular extension) biomarkers in predicting sig-
nificant disease. Furthermore, the potential utility of EN2 
to aid in the active surveillance versus immediate treat-
ment decision process may also be realised through its 
inclusion in continuous multivariable prediction models, 
such as nomograms [20]. There are a number of limita-
tions with our study in terms of the cohort size and single 
network. However, confirmatory studies are currently 
ongoing in centers in Europe and the USA and EN2 will 
be evaluated concurrently with other urine and serum 
biomarkers concurrently with MRI imaging in the PRO-
MIS study in the United Kingdom 
(http://www.controlled-trials.com/ISRCTN16082556). 
This study confirms a strong correlation between uri-
nary EN2 levels and both tumour volume and tumour 
stage in a prospective cohort as determined at RP. EN2 
levels were significantly higher in men with disease vo-
lumes previously used to delineate significant versus 
non-significant disease. This study justifies a larger mul-
ticenter evaluation of urinary EN2 levels as a biomarker 
of PC significance using cancer volume, pathological and 
PSA criteria. 
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